Our top pick for
NantKwest Inc is a biotechnology business based in the US. NantKwest shares (NK) are listed on the NASDAQ and all prices are listed in US Dollars. NantKwest employs 171 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$37.30|
|52-week range||$6.80 - $46.82|
|50-day moving average||$28.70|
|200-day moving average||$14.19|
|Wall St. target price||$18.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-2.36%|
|1 month (2021-09-17)||-2.86%|
|3 months (2021-07-16)||-1.37%|
|6 months (2021-04-16)||-17.73%|
|1 year (2020-10-16)||304.56%|
|2 years (2019-10-17)||2,982.64%|
|3 years (2018-10-17)||1,192.89%|
|5 years (2016-10-17)||498.72%|
Valuing NantKwest stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NantKwest's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NantKwest's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NantKwest's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||$111,000|
|Return on assets TTM||-36.2%|
|Return on equity TTM||-77.61%|
|Market capitalisation||$3.6 billion|
TTM: trailing 12 months
There are currently 3.9 million NantKwest shares held short by investors – that's known as NantKwest's "short interest". This figure is 27.9% down from 5.4 million last month.
There are a few different ways that this level of interest in shorting NantKwest shares can be evaluated.
NantKwest's "short interest ratio" (SIR) is the quantity of NantKwest shares currently shorted divided by the average quantity of NantKwest shares traded daily (recently around 1.1 million). NantKwest's SIR currently stands at 3.71. In other words for every 100,000 NantKwest shares traded daily on the market, roughly 3710 shares are currently held short.
However NantKwest's short interest can also be evaluated against the total number of NantKwest shares, or, against the total number of tradable NantKwest shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NantKwest's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NantKwest shares in existence, roughly 50 shares are currently held short) or 0.1547% of the tradable shares (for every 100,000 tradable NantKwest shares, roughly 155 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NantKwest.
Find out more about how you can short NantKwest stock.
We're not expecting NantKwest to pay a dividend over the next 12 months.
NantKwest's shares were split on a 8:1 basis on 16 August 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 8 shares. This wouldn't directly have changed the overall worth of your NantKwest shares – just the quantity. However, indirectly, the new 87.5% lower share price could have impacted the market appetite for NantKwest shares which in turn could have impacted NantKwest's share price.
Over the last 12 months, NantKwest's shares have ranged in value from as little as $6.8 up to $46.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantKwest's is 2.3862. This would suggest that NantKwest's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NantKwest, Inc. , a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.